Compare Cassava Sciences Inc (FLNA) vs Kraft Heinz Co (KHC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Kraft Heinz Co — how do they compare? Cassava Sciences Inc trades at $0.97 (market cap $47.75M), while Kraft Heinz Co trades at $24.7 (market cap $29.56B). The key difference: Kraft Heinz Co is far larger — about 619.1× Cassava Sciences Inc's market cap, and Kraft Heinz Co pays a 6.42% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | KHC | |
|---|---|---|
Market Cap | $47.75M | $29.56B |
Sector | Health | Consumer Staples |
52-Week High | $4.64 | $28.06 |
52-Week Low | $0.87 | $21.21 |
Enterprise Value | -$34.93M | $45.88B |
Dividend Yield | — | 6.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.995, up 3.75% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of -$0.18 beating expectations of -$0.225. Financials show negative cash flows and profitability, with ROE at -55.79% and net income of -$90.97M in 2025. Analyst consensus is strongly positive with 8 buy ratings out of 12.
Despite operational losses, FLNA's consistent earnings beats and strong analyst support suggest potential upside if clinical developments progress. Key risks include sustained cash burn, lack of revenue, and dependence on successful drug trials for Tuberous Sclerosis Complex. The stock remains speculative with high volatility expected.
Kraft Heinz (KHC) trades at $25.32, up 1.44% today, with a bearish technical signal but oversold RSI. The stock shows mixed fundamentals: earnings beat estimates in recent quarters, yet 2025 net income was -$5.85B, reflecting margin pressures. Revenue declined to $24.94B in 2025, while the P/E of 13.04 and P/B of 0.83 suggest undervaluation. Recent news highlights CEO Cahillane's strategy to boost marketing spend for growth, amid institutional selling by firms like Bank of America (Defense World, 2026-08-09).
Outlook remains cautious; the 6% dividend yield attracts income investors, but sustainability is questioned amid profit declines. Risks include persistent inflation and competitive headwinds. Analysts are mostly neutral (57.14% Hold), with a $24 consensus target, implying limited upside. The stock's trajectory hinges on successful execution of turnaround efforts to stabilize earnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Kraft Heinz Co
In July 2015, Kraft merged with Heinz to create the third-largest food and beverage manufacturer in North America behind PepsiCo and Nestle and the fifth-largest player in the world. Beyond its namesake brands, the combined firm's portfolio includes Oscar Mayer, Velveeta, and Philadelphia. Outside North America, the firm's global reach includes a distribution network in Europe and emerging markets that drive around one fifth of its consolidated sales base, as its products are sold in more than 190 countries and territories.
Read more on KHC →
